Background: Increased serum lipoprotein(a) [Lp(a)] and high-sensitivity C-reactive protein (hsCRP) concentrations are independent risk factors for coronary heart disease (CHD). Xuezhikang, an extract of cholestin, effectively lowers fasting cholesterol and triglyceride concentrations. We studied whether xuezhikang lowered Lp(a) and hsCRP concentrations.
Methods: We randomly divided 60 CHD patients into two groups to receive xuezhikang (1200 mg daily) or placebo for 6 weeks. The fasting hsCRP concentration and the postprandial changes of serum lipid concentrations at 2, 4, and 6 h after a high-fat meal (800 calories; 50 g of fat) were measured before and after the 6-week protocol.
Results: The two groups had similar baseline fasting lipid and hsCRP concentrations. The postprandial triglyceride and Lp(a) concentrations were significantly increased (P <0.05). After 6 weeks, the fasting and postprandial lipid concentrations decreased significantly in the xuezhikang group, accompanied by a significant reduction in fasting hsCRP concentration (P <0.001). The placebo group had no significant change in lipid concentrations, whereas the fasting serum hsCRP concentration was reduced significantly (P <0.05). The reduction in hsCRP was closely related to the changes in fasting Lp(a) concentration (r = 0.402; P <0.05) and triglyceride area under the curve (r = 0.441; P <0.001).
Conclusions: Xuezhikang effectively decreased fasting Lp(a) and postprandial triglyceride concentrations, which were associated with reductions of fasting hsCRP concentrations in CHD patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1373/49.8.1347 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Statins-Their Effect on Lipoprotein(a) Levels.
Rev Cardiovasc Med
January 2025
Department of Clinical and Experimental Pharmacology, Faculty of Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.
Lipoprotein(a) (Lp(a)) serum concentration plays a crucial role as a risk factor in cardiovascular diseases and is gaining more and more attention. Patients with elevated lipoprotein(a) levels are often prescribed statins as they also have high concentrations of low-density lipoprotein cholesterol (LDL-C). Statins are drugs that successfully decrease LDL-C, but their effectiveness in Lp(a) levels reduction is uncertain.
View Article and Find Full Text PDFPrevalence of Lp(a) in a real-world Portuguese cohort: implications for cardiovascular risk assessment.
Lipids Health Dis
January 2025
Department of Endocrinology, Diabetes and Metabolism, Local Health Unit of Santo António, Largo Professor Abel Salazar, Porto, 4099-001, Portugal.
Background: Cardiovascular disease (CVD) is a major cause of mortality worldwide, necessitating more refined strategies for risk assessment. Recently, lipoprotein(a) [Lp(a)] has gained attention for its distinctive role in atherosclerosis, yet its prevalence and impact for cardiovascular risk assessment are not well-documented in the Portuguese population. This study aimed to characterize Lp(a) levels in a real-world Portuguese cohort, investigating its prevalence and association with CVD risk.
View Article and Find Full Text PDFAssociation of LDL-cholesterol with prognosis in patients admitted for acutely decompensated heart failure.
Rev Port Cardiol
January 2025
Cardiology Department, Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal; Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal.
Introduction And Objectives: The association of low-density lipoprotein cholesterol (LDL-C) levels and prognosis in patients with heart failure (HF) remains uncertain. This study aimed to evaluate the prognostic significance of LDL-C in patients admitted for acutely decompensated HF and establish a safety cut-off value in this population.
Methods: This retrospective, observational study included 167 consecutive patients admitted for acute HF.
Pretreatment Lipoprotein(a) as a Biomarker for EGFR Mutation and Prognosis in Lung Adenocarcinoma.
Int J Gen Med
December 2024
Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, People's Republic of China.
Article Synopsis
- This study explores the relationship between pretreatment serum lipoprotein(a) [Lp(a)] levels and EGFR gene mutations in patients with advanced lung adenocarcinoma undergoing treatment with EGFR-TKIs.
- The research evaluated 338 patients and concluded that a higher Lp(a) level (above 20.48 mg/L) is linked to a lower rate of EGFR mutations (48.0% vs 65.5%).
- The findings also indicate that higher Lp(a) levels are associated with longer progression-free survival (16.1 months vs 9.6 months), suggesting it is a significant independent predictor for both EGFR mutations and PFS.
Lipoprotein(a) as a Predictor of Nonalcoholic Fatty Liver After Pancreatectomy.
Anticancer Res
January 2025
Department of Surgery, The Jikei University School of Medicine, Tokyo, Japan.
Background/aim: Lipoprotein(a) (Lp(a)) is a complex protein involved in the transport of insoluble lipids in plasma. Its expression is predominantly genetically determined, with 70% to over 90% influenced by the number of Kringle IV type 2 domains. This study investigated the association between preoperative serum Lp(a) level and development of post-pancreatectomy nonalcoholic fatty liver disease (NAFLD) in patients who underwent pancreatectomy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!